Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Arch Biopartners Inc
Arch Biopartners Inc logo

ARCH - Arch Biopartners Inc Reuters News

C$1.2 -0.0  -2.4%

Last Trade - 26/02/21

Sector
Healthcare
RiskRating
Adventurous
Size
Micro Cap
Style
Sucker Stock
Market Cap £41.5m
Enterprise Value £43.0m
Revenue £38.3k
Position in Universe 965th / 2684
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions ARCH Dividends
Reuters News
All News Reuters News Company Announcements
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
Fri 1:42pm News
BRIEF-Arch Biopartners Receives Ethics Committee Approval In Turkey To Dose Additional Patients In The Phase II Trial For LSALT Peptide
2nd Feb News
Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide
2nd Feb News
BRIEF-University Of Calgary Joins The Phase Ii Trial Of Lsalt Peptide For The Treatment Of Complications In Hospitalized Covid-19 Patients
5th Jan News
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
5th Jan News
Arch Biopartners Closes Non-Brokered Private Placement
29th Dec '20 News
Arch Biopartners Arranges Non-Brokered Private Placement
23rd Dec '20 News
BRIEF-Arch Biopartners Receives Government Of Canada Funding To Support Phase II Therapeutic Trial Of Metablok For Covid-19
15th Dec '20 News
Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19
15th Dec '20 News
BRIEF-Arch Biopartners Inc Says Veterans Affairs San Diego Healthcare System Has Started Recruiting Patients For Phase II Trial Of Its Lead Drug LSALT Peptide
10th Dec '20 News
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
10th Dec '20 News
BRIEF-Arch Biopartners Announces Dosing Of First Patient In Turkey In Phase II Trial Of LSALT Peptide To Treat COVID-19 Complications
5th Nov '20 News
Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19
5th Nov '20 News
BRIEF-First Patient Dosed In Phase Ii Trial To Treat Complications In Covid-19
16th Oct '20 News
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
16th Oct '20 News
BRIEF-Arch Biopartners Receives Approval From Turkish Ministry Of Health To Proceed With Phase II Trial For Lsalt Peptide
7th Oct '20 News
Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida
7th Oct '20 News
Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide
10th Sep '20 News
Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients
1st Sep '20 News
BRIEF-Arch Biopartners Obtains DTC Eligibility For Its Common Shares On OTCQB
21st Aug '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.